Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Nature Communications
Berko, Esther R ER; Witek, Gabriela M GM; Matkar, Smita S; Petrova, Zaritza O ZO; Wu, Megan A MA; Smith, Courtney M CM; Daniels, Alex A; Kalna, Joshua J; Kennedy, Annie A; Gostuski, Ivan I; Casey, Colleen C; Krytska, Kateryna K; Gerelus, Mark M; Pavlick, Dean D; Ghazarian, Susan S; Park, Julie R JR; Marachelian, Araz A; Maris, John M JM; Goldsmith, Kelly C KC; Radhakrishnan, Ravi R; Lemmon, Mark A MA; Mossé, Yaël P YP
Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria.
American Journal Of Human Genetics
Pejaver, Vikas V; Byrne, Alicia B AB; Feng, Bing-Jian BJ; Pagel, Kymberleigh A KA; Mooney, Sean D SD; Karchin, Rachel R; O'Donnell-Luria, Anne A; Harrison, Steven M SM; Tavtigian, Sean V SV; Greenblatt, Marc S MS; Biesecker, Leslie G LG; Radivojac, Predrag P; Brenner, Steven E SE; ,
Publication Date: 2022-12-01
Variant appearance in text: ALK: D1203N; rs759845895
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.
Pugh, Trevor J TJ; Bell, Jonathan L JL; Bruce, Jeff P JP; Doherty, Gary J GJ; Galvin, Matthew M; Green, Michelle F MF; Hunter-Zinck, Haley H; Kumari, Priti P; Lenoue-Newton, Michele L ML; Li, Marilyn M MM; Lindsay, James J; Mazor, Tali T; Ovalle, Andrea A; Sammut, Stephen-John SJ; Schultz, Nikolaus N; Yu, Thomas V TV; Sweeney, Shawn M SM; Bernard, Brady B; ,
Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.
Frontiers In Oncology
Shen, Fangfang F; Liang, Naixin N; Fan, Zaiwen Z; Zhao, Min M; Kang, Jing J; Wang, Xifang X; Hu, Qun Q; Mu, Yongping Y; Wang, Kai K; Yuan, Mingming M; Chen, Rongrong R; Guo, Wei W; Dong, Guilan G; Zhao, Jun J; Bai, Jun J
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
Cancer Medicine
Kwon, Minsuk M; Ku, Bo Mi BM; Olsen, Steve S; Park, Sehhoon S; Lefterova, Martina M; Odegaard, Justin J; Jung, Hyun-Ae HA; Sun, Jong-Mu JM; Lee, Se-Hoon SH; Ahn, Jin Seok JS; Park, Keunchil K; Ahn, Myung-Ju MJ
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Cancers
Descourt, Renaud R; Pérol, Maurice M; Rousseau-Bussac, Gaëlle G; Planchard, David D; Mennecier, Bertrand B; Wislez, Marie M; Cadranel, Jacques J; Cortot, Alexis Benjamin AB; Guisier, Florian F; Galland, Loïck L; Do, Pascal P; Schott, Roland R; Dansin, Éric É; Arrondeau, Jennifer J; Auliac, Jean-Bernard JB; Geier, Margaux M; Chouaïd, Christos C
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Frontiers In Endocrinology
Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C
A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
Jto Clinical And Research Reports
Zhu, Viola W VW; Nagasaka, Misako M; Madison, Russell R; Schrock, Alexa B AB; Cui, Jean J; Ou, Sai-Hong Ignatius SI
Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report.
Oncotargets And Therapy
Yao, Bin B; Han, Xue X; Pang, Linrong L; Xu, Caihong C; Liu, Sisi S; Cheng, Xiaochun X; Chen, Jun J
Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Translational Oncology
Ou, Sai-Hong Ignatius SI; Nagasaka, Misako M; Brazel, Danielle D; Hou, Yujie Y; Zhu, Viola W VW
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Therapeutic Advances In Medical Oncology
Frost, Nikolaj N; Christopoulos, Petros P; Kauffmann-Guerrero, Diego D; Stratmann, Jan J; Riedel, Richard R; Schaefer, Monica M; Alt, Jürgen J; Gütz, Sylvia S; Christoph, Daniel C DC; Laack, Eckart E; Faehling, Martin M; Fischer, Richard R; Fenchel, Klaus K; Haen, Sebastian S; Heukamp, Lukas L; Schulz, Christian C; Griesinger, Frank F